The co-CEOs and co-founders of Amylyx Pharmaceuticals discussed their immediate thoughts to the recent FDA AdComm meeting, which voted against evidence of efficacy for AMX0035 in ALS. [WATCH TIME: 3 minutes]
Josh Cohen, BSc
Advertisement
Articles by Josh Cohen, BSc
Advertisement
Latest Updated Articles
Reactions to FDA Advisory Panel Decision on AMX0035: Justin Klee; Josh Cohen, BScPublished: May 19th 2022 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Understanding VTX3232’s Effects on Patients with Early-Stage Parkinson Disease
2
Ocrelizumab’s Encouraging Treatment Effects Across Conception Delivery and Breastfeeding
3
Key Diagnostic Pearls for NMOSD Recognition and Testing: Elena Grebenciucova, MD
4
2025 CNS Annual Meeting: Top Expert Interviews and Key Takeaways
5
